Klotho Neurosciences IncNASDAQ:KLTONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3529
- TODAY'S CHANGE (%)0.0019 (0.5413%)
- Bid / Lots0.3415/ 3
- Ask / Lots0.3800/ 149
- Open / Previous Close0.3600 / 0.3510
- Day Range
- 52 Week Range
- Volume174,589
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KLTO |
|---|---|---|
| 09:32 ET | 6396 | 0.355 |
| 09:39 ET | 100 | 0.3998 |
| 09:42 ET | 110 | 0.3998 |
| 09:44 ET | 1420 | 0.3552 |
| 09:46 ET | 1300 | 0.3998 |
| 09:48 ET | 8900 | 0.3552 |
| 09:51 ET | 600 | 0.36 |
| 09:57 ET | 300 | 0.3995 |
| 10:00 ET | 100 | 0.3572 |
| 10:02 ET | 1011 | 0.3876 |
| 10:04 ET | 120 | 0.3572 |
| 10:08 ET | 100 | 0.3572 |
| 10:09 ET | 1160 | 0.3572 |
| 10:11 ET | 120 | 0.3572 |
| 10:13 ET | 100 | 0.3572 |
| 10:15 ET | 620 | 0.355 |
| 10:20 ET | 130 | 0.356 |
| 10:24 ET | 1926 | 0.355 |
| 10:26 ET | 1900 | 0.355 |
| 10:27 ET | 3255 | 0.355 |
| 10:29 ET | 341 | 0.351 |
| 10:33 ET | 100 | 0.346 |
| 10:36 ET | 130 | 0.331 |
| 10:45 ET | 474 | 0.36475 |
| 11:00 ET | 360 | 0.335 |
| 11:14 ET | 1450 | 0.3355 |
| 11:16 ET | 445 | 0.364 |
| 11:18 ET | 300 | 0.374 |
| 11:21 ET | 3430 | 0.337 |
| 11:23 ET | 1800 | 0.367501 |
| 11:25 ET | 11820 | 0.3356 |
| 11:27 ET | 10000 | 0.3677 |
| 11:30 ET | 100 | 0.3355 |
| 11:32 ET | 7273 | 0.3355 |
| 11:34 ET | 300 | 0.335 |
| 11:36 ET | 5560 | 0.36 |
| 11:38 ET | 14298 | 0.356958 |
| 11:39 ET | 5700 | 0.353383 |
| 11:41 ET | 585 | 0.3599 |
| 11:43 ET | 20613 | 0.3311 |
| 11:48 ET | 1585 | 0.3589 |
| 11:50 ET | 810 | 0.36 |
| 11:52 ET | 100 | 0.3401 |
| 11:57 ET | 100 | 0.3402 |
| 12:01 ET | 938 | 0.36 |
| 12:03 ET | 3200 | 0.3402 |
| 12:14 ET | 100 | 0.3415 |
| 12:17 ET | 100 | 0.343 |
| 12:21 ET | 110 | 0.343 |
| 12:24 ET | 100 | 0.3438 |
| 12:26 ET | 500 | 0.36 |
| 12:33 ET | 5000 | 0.352333 |
| 12:35 ET | 100 | 0.344 |
| 12:37 ET | 1330 | 0.348 |
| 12:39 ET | 2100 | 0.347 |
| 12:50 ET | 910 | 0.355 |
| 12:53 ET | 100 | 0.3416 |
| 01:02 ET | 700 | 0.3417 |
| 01:04 ET | 100 | 0.3416 |
| 01:08 ET | 100 | 0.3416 |
| 01:13 ET | 3000 | 0.34 |
| 01:18 ET | 200 | 0.332 |
| 01:20 ET | 400 | 0.332 |
| 01:27 ET | 100 | 0.3333 |
| 01:31 ET | 120 | 0.3333 |
| 01:33 ET | 1000 | 0.348 |
| 01:40 ET | 100 | 0.3336 |
| 01:45 ET | 100 | 0.334 |
| 01:47 ET | 100 | 0.3417 |
| 01:49 ET | 300 | 0.356 |
| 01:58 ET | 2615 | 0.3333 |
| 02:00 ET | 4191 | 0.3825 |
| 02:03 ET | 11688 | 0.3825 |
| 02:14 ET | 100 | 0.3421 |
| 02:16 ET | 304 | 0.3474 |
| 02:23 ET | 100 | 0.3422 |
| 02:27 ET | 1925 | 0.3423 |
| 02:32 ET | 172 | 0.3423 |
| 02:39 ET | 100 | 0.343 |
| 02:45 ET | 100 | 0.343 |
| 02:50 ET | 100 | 0.3423 |
| 02:54 ET | 300 | 0.343 |
| 02:57 ET | 100 | 0.343 |
| 02:59 ET | 100 | 0.343 |
| 03:03 ET | 100 | 0.343 |
| 03:10 ET | 100 | 0.343 |
| 03:12 ET | 100 | 0.343 |
| 03:17 ET | 392 | 0.343 |
| 03:26 ET | 200 | 0.352 |
| 03:32 ET | 200 | 0.3534 |
| 03:37 ET | 700 | 0.3534 |
| 03:46 ET | 500 | 0.353 |
| 03:48 ET | 1002 | 0.3529 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Klotho Neurosciences Inc | 5.3M | -13.9x | --- |
Clearmind Medicine Inc | 5.4M | -0.1x | --- |
Carmell Corp | 5.1M | -0.2x | --- |
Bionomics Ltd | 5.1M | 0.0x | --- |
Weed Inc | 5.0M | -7.1x | --- |
Enzon Pharmaceuticals Inc | 5.6M | 23.0x | -60.21% |
Company Information
Klotho Neurosciences, Inc. is a biopharmaceutical company. The Company is engaged in the development of disease-modifying cell and gene therapies using a patented secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders, such as amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease. The Company’s portfolio consists of its proprietary cell and gene therapy programs using deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) as therapeutics and diagnostics. Its gene therapy programs include KLTO-202, KLTO-101, and KLTO-301. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The Company has licensed the anti-aging protein called α-Klotho for gene therapy to stop the progression of, or prevent, neurodegenerative diseases.
Contact Information
- Headquarters
- 1115 Broadway, 12Th FloorNEW YORK, NY, United States 10010
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Joseph Sinkule
- Chief Financial Officer
- Jeffrey LeBlanc
- Chief Business Officer, Director
- Peter Moriarty
- Independent Director
- Shalom Hirschman
- Independent Director
- Jon Mcgarity
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 15.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.03 |
Book Value | $2.17 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
